TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸ARMP

Armata Pharmaceuticals, Inc. Common Stock

NYSE
$5.89
▼ $2.03 (-25.6%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $14.98L $5.66-7.5%
$14.98$13.12$11.25$9.39$7.52$5.66$5.89
RSI (14)
Intraday · 15-minSell-20RSI 49DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong sell-50
RSI (14)35
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Below lower band
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$5.70
Resistance
$8.12
  • Price is below its 50-day average (medium-term weakness).
  • Price is below the lower Bollinger Band (stretched to the downside).

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
+34.1%
Buy & hold
+99.7%
Trades
7
Win rate
29%

$100,000.00 invested would be worth $134,150.93 (+34.2%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Armata Pharmaceuticals, Inc.· Biotechnology

source: yahoo

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Sector
Healthcare
Industry
Biotechnology
Employees
61
Headquarters
Los Angeles, United States
www.armatapharma.com ↗

Fundamentals· Retail

demo data

Live data was unavailable (the free feed can be rate-limited or blocked by region/host), so sample figures are shown. Set FINNHUB_API_KEY for a reliable fallback.

Market cap
$982.35B
P/E
23.7
P/B
3.7
EPS
$21.70
Div yield
1.4%
Profit margin
25.8%
ROE
15.4%
Debt / Equity
0.17
Beta
1.57
52-week range
$359.55 – $642.05
52-week low · $359.550% of rangehigh · $642.05

Recent news

News sentiment:▲ Positive1↑ · 0↓ · 7–
  • Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday— Neutral
    MT Newswires · 23 Jun 2026
  • Armata Pharmaceuticals Receives Additional $2.5 Million in Funding From US Department of Defense— Neutral
    MT Newswires · 23 Jun 2026
  • Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02— Neutral
    PR Newswire · 23 Jun 2026
  • Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Fundamental data is informational only — not investment advice.

▲ Positive
Insider Monkey · 19 Jun 2026
  • Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update— Neutral
    PR Newswire · 13 May 2026
  • Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02— Neutral
    PR Newswire · 07 May 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.